Genetic tests: Clinical validity and clinical utility

Current Protocols in Human Genetics

Volumn , Issue SUPPL.81, 2014, Pages

  Burke, Wylie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Clinical utility; Clinical validity; Penetrance; Predictive value

Indexed keywords

FEMALE; GENETIC SCREENING; HETEROZYGOTE DETECTION; HUMAN; MALE; PEDIGREE; VALIDATION STUDY;

FEMALE; GENETIC TESTING; HETEROZYGOTE DETECTION; HUMANS; MALE; PEDIGREE;

EID: 84905695420     PISSN: 19348266     EISSN: 19348258     Source Type: Journal    
DOI: 10.1002/0471142905.hg0915s81     Document Type: Article

References (34)

1. Abboud, R.T., Ford, G.T., and Chapman, K.R. Standards Committee of the Canadian Thoracic Society. 2001. α1-antitrypsin deficiency: A position statement of the Canadian Thoracic Society. Can. Respir. J. 8:81-88.
2. Allen, K.J., Gurrin, L.C., Constantine, C.C., Osborne, N.J., Delatycki, M.B., Nicoll, A.J., McLaren, C.E., Bahlo, M., Nisselle, A.E., Vulpe, C.D., Anderson, G.J., Southey, M.C., Giles, G.G., English, D.R., Hopper, J.L., Olynyk, J.K., Powell, L.W., and Gertig, D.M. 2008. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med. 358:221-230.
3. Altshuler, D. and Daly, M. 2007. Guilt beyond a reasonable doubt. Nat. Genet. 39:813-815.
4. Asberg, A., Hveem, K., Kannelønning, K., and Irgens, W.Ø. 2007. Penetrance of the C28Y/C282Y genotype of theHFE gene. Scand. J. Gastroenterol. 42:1073-1077.
5. Ashley-Koch, A., Yang, Q., and Olney, R.S. 2000. Sickle hemoglobin (Hb S) allele and sickle cell disease. Am. J. Epidemiol. 151:839-845.
6. Begg, C.B. 2002. On the use of familial aggregation in population-based case probands for calculating penetrance. J. Natl. Cancer Inst. 94:1221-1226.
7. Beutler, E. 2007. Iron storage disease: Facts, fiction and progress. Blood Cells Mol. Dis. 39:140-147.
8. Brandi, M.L., Gagel, R.F., Angeli, A., Bilezekian, J.P., Beck-Peccoz, P., Bordi, C., Conte-Devolx, B., Falchetti, A., Gheri, R.G., Libroia, A., Lips, C.J., Lombardi, C.,Mannelli, M., Pacini, F., Pnder, B.A., Raue, F., Skogseid, B., Tamburrano, G., Thakker,R.V., Thompson,N.W., Tomassetti, P., Tonelli, F., Wells, S.A. Jr., and Mar, S.J. 2001. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86:5658-5671.
9. Burke, W. and Austin, M.A. 2002. Genetic risk in context: Calculating the penetrance of BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 94:1185-1187.
10. Burke, W. and Psaty, B.M. 2007. Personalized medicine in the era of genomics. JAMA 298:1682-1684.
11. Burke,W., Atkins, D., Gwinn, M., Guttmacher, A., Haddow, J., Lau, J., Palomaki, G., Press, N., Richards, C.S., Wideroff, L., and Wiesner, G.L. 2002. Genetic test evaluation: Information needs of clinicians, policy-makers and the public. Am. J. Epidemiol. 156:311-318.
12. Ford, D., Easton, D.F., Bishop, D.T., Narod, S.A., and Goldgar, D.E. 1994. Risks of cancer in BRCA1-mutation carriers: Breast Cancer Linkage Consortium. Lancet 343:692-695.
13. Gan, E.K., Powell, L.W., and Olynyk, J.K. 2011. Natural history and management of HFEhemochromatosis. Semin. Liver Dis. 31:293-301.
14. Grody,W.W., Thompson, B.H., Gregg, A.R., Bean, L.H.,Monaghan, K.G., Schneider,A., and Lebo, R.V. 2013. ACMG position statement on prenatal/ preconception expanded carrier screening. Genet. Med. 15:482-483.
15. Hansen, E., Imperatore, P., and Burke, W. 2001. HFE gene and hemochromatosis: A HuGE review. Am. J. Epidemiol. 154:193-206.
16. Holtzman, N.A. andWatson, M.S. 1999. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing. Johns Hopkins University Press, Baltimore, Maryland.
17. Humphries, S., Ridker, P.M., and Talmud, P.J. 2004. Genetic testing for cardiovascular disease susceptibility: Auseful clinical management tool or possible misinformation. Arteroscler. Thromb. Vasc. Biol. 24:1-9.
18. Janssens, A.C., Ioannidis, J.P., van Duijn, C.M., Little, J., Khoury, M.J.; GRIPS Group. 2011. Strengthening the reporting of Genetic Risk Prediction Studies: The GRIPS statement. Genet Med. 13:453-456.
19. Jarvinen, H.J., Aarnio, M., Mustonene, H., Aktan-Collan, K., Aaltonen, L.A., Peltomaki, P., De La Chapelle, A., andMecklin, J.P. 2000. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829-834.
20. Khoury, M.J., Janssens, A.C., and Ransohoff, D.F. 2013. How can polygenic inheritance be used in population screening for common diseases? Genet Med. 15:437-443.
21. Lebo, R.V. and Grody, W.W. 2007. Testing and reporting ACMG cystic fibrosis mutation panel results. Genet. Test. 11:11-31.
22. Levy-Lahad, E. and Friedman, E. 2007. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 96:11-15.
23. Nebert, D.W., Zhang, G., and Vesell, E.S. 2008. From human genetics and genomics to pharmacogenetics and pharmacogenomics: Past lessons, future directions. Drug Metab. Rev. 40:187-224.
24. Raue, F. and Frank-Raue, K. 2010. Update multiple endocrine neoplasia type 2. Fam. Cancer 9:449-457.
25. Shuen, A.Y. and Foulkes,W.D. 2011. Inherited mutations in breast cancer genes-risk and response. J. Mammary Gland Biol. Neoplasia 16:3-15.
26. Simonds, N.I., Khoury, M.J., Schully, S.D., Armstrong, K., Cohn, W.F., Fenstermacher, D.A., Ginsburg, G.S., Goddard, K.A., Knaus, W.A., Lyman, G.H., Ramsey, S.D., Xu, J., and Freedman, A.N. 2013. Comparative effectiveness research in cancer genomics and precision medicine: Current landscape and future prospects. J. Natl. Cancer Inst. 105:929-936.
27. Sivakumaran, S., Agakov, F., Theodoratou, E., Prendergast, J.G., Zgaga, L., Manolio, T., Rudan, I., McKeigue, P., Wilson, J.F., and Campbell, H. 2011. Abundant pleiotropy in human complex diseases and traits. Am. J. Hum. Genet. 89:607-618.
28. Skinner, M.A., Moley, J.A., Dilley, W.G., Owzar, K., Debenedetti, M.K., and Wells, S.A. Jr. 2005. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N. Engl. J. Med. 353:1105-1113.
29. U.S. Preventive Services Task Force. 2006. Screening for hemochromatosis: Recommendation statement. Ann. Intern. Med. 145:204-208.
30. Vasen, H.F., Blanco, I., Aktan-Collan, K., Gopie, J.P.,Alonso, A.,Aretz, S., Bernstein, I.,Bertario, L., Burn, J., Capella, G., Colas, C., Engel, C., Frayling, I.M., Genuardi, M., Heinimann, K., Hes, F.J., Hodgson, S.V., Karagiannis, J.A., Lalloo, F., Lindblom, A., Mecklin, J.P., Møller, P., Myrhoj, T., Nagengast, F.M., Parc, Y., Ponz de Leon, M., Renkonen-Sinisalo, L., Sampson, J.R., Stormorken, A., Sijmons, R.H., Tejpar, S., Thomas, H.J., Rahner, N., Wijnen, J.T., J̈arvinen, H.J., M̈oslein, G.; Mallorca group. 2013. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): Recommendations by a group of European experts. Gut 62:812-823.
31. Wilken, B. 2001. Rare disease and the assessment of intervention: What sorts of clinical trials can we use? J. Inherit Metab. Dis. 24:291-298.
32. Woolf, S.H. 2000. Evidence-based medicine and practice guidelines: An overview. Cancer Control 7:362-367.
33. World Health Organization. 1997. α1-Antitypsin deficiency: Memorandum from a WHO meeting. Bull. World Health Org. 75:397-415.
34. Zamora, N.P., Pla, R.V., Del Rio, P.G., Margaleff, R.J., Frias, F.R., and Ronsano, J.B. 2008. Intravenous human plasma-derived augmentation therapy in alpha 1-antitrypsin deficiency: From pharmacokinetic analysis to individualizing therapy. Ann. Pharmacother. 42:640-646